癌胚纤维连接蛋白mRNA在甲状腺乳头状癌和未分化癌中的限制性表达：一项原位杂交研究

Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study.

作者信息

Takano T, Matsuzuka F, Miyauchi A, Yokozawa T, Liu G, Morita S, Kuma K, Amino N

机构信息

Department of Laboratory Medicine, Osaka University Medical School, Suita, Japan.

出版信息

Br J Cancer. 1998 Jul;78(2):221-4. doi: 10.1038/bjc.1998.468.

DOI:10.1038/bjc.1998.468

PMID:9683297

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2062902/

Abstract

Restricted expression of oncofetal fibronectin mRNA in the tissues of thyroid papillary and anaplastic carcinoma has recently been shown by both Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). Oncofetal fibronectin mRNA can be a target of gene diagnosis and targeted gene therapy, provided it is expressed in all cancer cells in the tissues. To investigate this criterion in thyroid cancer tissues, we measured their expression of oncofetal fibronectin mRNA using in situ hybridization. An abundant expression of oncofetal fibronectin mRNA was found in all the observed cancer cells of six papillary carcinomas and an anaplastic carcinoma, but not in the tissues of normal thyroid, Graves' disease, adenomatous goitre, follicular adenoma, follicular carcinoma or medullary carcinoma. This result encourages us to establish gene diagnosis of thyroid papillary and anaplastic carcinomas by detecting oncofetal fibronectin mRNA in biopsies.

摘要

最近，通过Northern印迹分析和逆转录聚合酶链反应（RT-PCR）均已表明，癌胚纤连蛋白mRNA在甲状腺乳头状癌和间变性癌组织中表达受限。如果癌胚纤连蛋白mRNA在组织中的所有癌细胞中均有表达，那么它可以成为基因诊断和靶向基因治疗的靶点。为了研究甲状腺癌组织中的这一标准，我们使用原位杂交技术检测了它们癌胚纤连蛋白mRNA的表达。在6例乳头状癌和1例间变性癌的所有观察到的癌细胞中均发现了丰富的癌胚纤连蛋白mRNA表达，但在正常甲状腺、格雷夫斯病、腺瘤性甲状腺肿、滤泡性腺瘤、滤泡性癌或髓样癌组织中未发现。这一结果促使我们通过检测活检组织中的癌胚纤连蛋白mRNA来建立甲状腺乳头状癌和间变性癌的基因诊断方法。